WeVote
Log In

Bill

Bill

HB 3554

Relating to establishment of the Texas Rare Disease Advisory Council.

89th Legislature (2025) Introduced by Nicole Collier and 7 co-sponsors

Texas establishes a Rare Disease Advisory Council to coordinate policy recommendations and support services for patients with rare and orphan diseases.

Received from the House
#educationagency #texas(v9941) #governor(i0375) #health&humanservicescommission(v0177) #health--otherdiseases&medicalconditions(i0383) #insurance #texasdepartmentof(v0006) #nurses&nurseaides(s2704) #pharmacies&pharmacists(s1192) #physicians(s1282) #rarediseaseadvisorycouncil #texas(v1220) #statehealthservices #departmentof(v0463) #stateagencies #boards&commissions--newlyproposed(i0773)
0
WeVote Research Nonpartisan
Bill Summary · HB 3554

Legislative bill overview

HB 3554 establishes the Texas Rare Disease Advisory Council, a new state advisory body designed to coordinate efforts related to rare diseases affecting Texans. The council would bring together stakeholders to provide recommendations on policy, research, and support services for patients with rare and orphan diseases.

Why is this important

Rare diseases collectively affect millions of Americans but individually impact small populations, making them low research priorities for pharmaceutical companies and challenging to diagnose. Creating a dedicated advisory council helps ensure Texas develops coordinated strategies for patient support, clinical expertise access, and disease awareness in an otherwise fragmented healthcare landscape.

Potential points of contention

  • Budget and staffing: The bill's fiscal impact depends on council size, meeting frequency, and administrative support—details that could impose unfunded mandates on state agencies
  • Council composition and influence: Determining who sits on the council and how much weight their recommendations carry raises questions about stakeholder representation versus state control
  • Scope of authority: Clarification needed on whether the council has advisory-only powers or can influence state funding, medical licensing, or pharmaceutical pricing decisions

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.